개요
Drug Discovery 아웃소싱 서비스는 다양한 치료 영역과 질병에 대한 신약의 발견과 개발을 촉진하기 위한 과학적, 기술적 서비스 범위를 의미합니다. Drug Discovery 과정에는 질병 과정에 관여하는 단백질, 유전자 등 잠재적인 Drug Discovery 표적을 확인하고 그 치료 가능성을 검증하는 표적 확인이 포함됩니다. 약품화학, 흡수·분포·대사·배설·독성 ADME-TOX 시험을 통한 체내 약물 거동 및 잠재적 부작용 평가, 약리학적 시험을 통한 유효성·안전성·약리학적 특성 평가, 전임상 개발 및 제제 개발에 이은 임상시험 등이 포함됩니다.
시장 역학 : 촉진요인과 저해요인
AI를 활용한 Drug Discovery 방법론의 부상
AI를 활용하고자 하는 기업은 단편적인 데이터뿐만 아니라 전체 데이터에 대한 전체적인 그림을 그려야 합니다. 이를 위해서는 계산팀과 실험팀이 협력하고, 워크플로우를 통합하고, 영역과 장소를 넘어 데이터를 공유할 수 있는 연구 인프라가 필요하며, AI의 도움을 받아 얻은 결과를 재현할 수 있도록 신중한 프로세스와 방법론의 표준화가 필요합니다.
예를 들어, 2023년 7월 키세이제약은 AI 의약품 '마키아'를 발표하면서 익토스(Iktos)의 AI Drug Discovery 시스템 'Makya'를 도입했습니다. 이를 통해 AI 기술을 활용해 표적 기준에 적합한 신규 저분자를 신속하게 설계할 수 있어 Drug Discovery 속도를 높일 수 있습니다.
또한 2023년 5월, 구글 클라우드는 생명공학 기업, 제약사 및 공공 기관을 위해 Drug Discovery 및 정밀 의료를 가속화할 수 있는 두 가지 새로운 AI 기반 생명과학 솔루션을 발표했습니다. 전 세계에서 사용할 수 있는 Target and Lead Identification Suite는 연구자들이 아미노산 기능을 식별하고 단백질 구조를 예측할 수 있도록 돕고, Multiomics Suite는 유전체 데이터 발견과 해석을 가속화하고 기업이 정밀 치료법을 설계할 수 있도록 돕습니다.
또한, 만성질환의 증가, 생물학적 제제 시장의 확대, R&D 시설의 증가 등의 요인이 약물전달 시장을 확대시키고 있으며, Al 통합 및 헬스케어의 디지털화와 같은 최신 기술 발전은 시장에 새로운 기회를 창출하고 있습니다.
시장 역학 : 저해요인
세계 Drug Discovery 아웃소싱 시장의 성장을 저해할 것으로 예상되는 주요 요인 중 하나는 높은 의약품 개발 비용입니다. 의약품 개발은 비용이 많이 들고 시간이 오래 걸리는 장기적인 과정입니다. Drug Discovery를 위한 전임상시험과 관련된 높은 비용이 가장 큰 문제입니다. 또한, 의약품 제조에 대한 엄격한 규정과 규제, 지적재산권, CMO의 규제 요건 미준수 위험 등 다른 요인들도 예측 기간 동안 시장 성장을 저해하는 요인으로 작용할 수 있습니다.
목차
제1장 조사 방법과 조사 범위
제2장 정의와 개요
제3장 주요 요약
제4장 시장 역학
- 영향요인
- 성장 촉진요인
- AI를 활용한 Drug Discovery 방법의 대두
- 만성질환 증가
- 성장 억제요인
- 기회
- 영향 분석
제5장 산업 분석
- Porter's Five Forces 분석
- 공급망 분석
- 가격 분석
- 규제 분석
- 파이프라인 분석
- 미충족 수요
- DMI 의견
제6장 COVID-19 분석
제7장 서비스 유형별
제8장 의약품 유형별
제9장 치료 분야별
제10장 최종사용자별
- 수탁연구기관
- 제약·바이오테크놀러지 기업
- 학술기관
- 기타
제11장 지역별
- 북미
- 유럽
- 남미
- 아시아태평양
- 중동 및 아프리카
제12장 경쟁 상황
- 경쟁 시나리오
- 시장 상황/점유율 분석
- M&A 분석
제13장 기업 개요
- ThermoFisher Scientific
- 기업 개요
- 제품 포트폴리오와 설명
- 재무 개요
- 주요 발전
- Charles River Laboratories International, Inc
- WuXi AppTec Co., Ltd.,
- Albany Molecular Research, Inc.,
- Aragen Life Sciences Ltd
- Sygnature Discovery,
- Pharmaron Beijing Co., Ltd.,
- Domainex Ltd.,
- Jubilant Biosys Ltd.
- Evotec
제14장 부록
ksm
Overview
Drug discovery outsourcing services refer to the range of scientific and technological services to facilitate the discovery and development of new drugs for various therapeutic areas or diseases. The drug discovery process includes target identification to identify potential drug targets, such as proteins or genes involved in disease processes, and validate their therapeutic potential. Medicinal chemistry, ADME-TOX studies which are absorption, distribution, metabolism, excretion, and toxicity to assess the behaviour of the drug within the body and its potential adverse effects, pharmacology studies to assess the efficacy, safety and pharmacological properties and preclinical development and formulation development followed by clinical trials.
Market Dynamics: Drivers and Restraints
Rise in the AI-enabled drug discovery methods
Companies hoping to leverage AI need a full view of all their data, not just bits and pieces. This demands a research infrastructure that lets computational and experimental teams collaborate, uniting workflows and sharing data across domains and locations. Careful process and methodology standardization are also needed to ensure that results obtained with the help of AI are repeatable.
For instance, in July 2023, kissei Pharmaceutical Co., Ltd. Introduced Makya, an AI drug discovery system from Iktos. This will enable the rapid design of new small molecules suitable for target criteria using AI technology, leading to an increase in the speed of drug discovery and development.
Moreover, in May 2023, Google Cloud announced two new AI-powered life sciences solutions to accelerate drug discovery and precision medicine for biotech companies, pharmaceutical firms, and public sector organizations. Available worldwide, the Target and Lead Identification Suite helps researchers better identify the function of amino acids and predict the structure of proteins; and the Multiomics Suite accelerates the discovery and interpretation of genomic data, helping companies design precision treatments.
Furthermore, factors like the rise in chronic diseases, expanding biologics market, and increasing research and development facilities are increasing the pharmaceutical drug delivery market, latest technological advancements such as Al integration and healthcare digitization create new opportunities for the market.
Market Dynamics: Restraint
One of the key factors expected to hamper the growth of the global drug discovery outsourcing market is the high cost of drug development. Drug development is an expensive, time-consuming, and long-term process. Higher costs associated with preclinical studies for drug discovery are the biggest challenge. Also, other factors like stringent rules & regulations for drug manufacturing, intellectual property rights, Risk of non-compliance with regulatory requirements by CMO and others factors hamper the market growth during the forecast period.
Segment Analysis
The global drug discovery outsourcing services market is segmented based on service type, drug type, therapeutic areas, end user and region.
The biology services segment from the service type segment accounted for approximately 41.7% of the drug discovery outsourcing services market share
The biology services segment from the service type segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Biological services encompass a range of specialized offerings that involve the study and manipulation of biological systems, such as cells, tissues, and biomolecules, to facilitate the identification and development of potential therapeutic compounds. Biological services play a pivotal role in assessing the interactions between complex potential drug candidates and living organisms at the cellular and molecular levels.
For instance, in January 2023, BenchSci is excited to announce the launch of our latest technology that aims to transform and improve outcomes and timelines for this crucial stage of drug discovery. ASCEND by BenchSci, our revolutionary new AI software platform has the potential to fundamentally change preclinical research. Building on the success of our AI-assisted reagent selection application, we've developed new applications to empower scientists to discover biological connections, dramatically reduce trial-and-error experimentation and uncover risks early to move the most promising projects forward faster.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the technological advancements, presence of well-established research infrastructure & key players, and higher investments in drug discovery R&D, acquisitions with key players, rising need for efficiency, quality, and innovation are expected to contribute to market growth.
For instance, in April 2022, Charles River Laboratories International and Valo Health launched Logica, an AI-powered drug solution that translates clients' biological insights into optimized preclinical assets. The solution uses Valo's AI-powered Opal Computational Platform and Charles River's preclinical expertise to provide clients with a single integrated offering, translating targets to candidate nominations. The partnership aims to integrate Charles River's laboratory capabilities with AI-driven molecular design, providing clients with advanced leads and candidates while tying client costs to value generation.
Moreover, in December 2021, Labcorp stated that it had acquired Toxikon Corporation, a contract research company offering nonclinical testing services. The addition of Toxikon to LabCorp drug development enhances the company's strong nonclinical development portfolio and assists in generating a strategic footprint for the company to partner with pharmaceutical and biotechnology clients.
COVID-19 Impact Analysis
COVID-19 had a substantial impact on the drug discovery outsourcing services market owing to the high demand for vaccine discovery by various pharmaceutical and biotech companies in the past three years. Drug discovery outsourcing has become a key aspect of developing effective treatments against the virus. For instance, in June 2021, Catalent, Inc. collaborated with Moderna, Inc. for the manufacturing of the Moderna COVID-19 vaccine and potentially other investigational programs in Moderna's pipeline at Catalent's biologics facility in Bloomington, Indiana.
Market Segmentation
By Service Type
- Medical Chemistry Services
- Biology Services
By Drug Type
- Small Molecule
- Large Molecules (Biopharmaceuticals)
By Therapeutic Areas
- Oncology
- Infectious Disease
- Respiratory Disease
- Cardiovascular
- Gastrointestinal
- Others
By End User
- Contract Research Organizations
- Pharmaceutical & Biotechnology Companies
- Academic Institutes
- Others
By Region
- North America
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Rest of Europe
- South America
- Brazil
- Argentina
- Rest of South America
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Middle East and Africa
Competitive Landscape
major global players in the market include: ThermoFisher Scientific, Charles River Laboratories International Inc., WuXi AppTec Co.Ltd., Albany Molecular Research, Inc., Aragen Life Sciences Ltd, Sygnature Discovery, Pharmaron Beijing Co. Ltd, Domainex Ltd., Jubilant Biosys Ltd., Evotec and among others.
Key Developments
- In November 2022, Sanofi and Insilico Medicine, a clinical-stage biotechnology company, inked a USD 1200 million Drug Development Deal. The agreement will see Sanofi use Insilico's AI platform, Pharma.AI, to advance drug development in up to six new targets.
- In October 2022, Amphista Therapeutics, a biotechnology company focusing on drug discovery projects that use targeted protein degradation (TPD), collaborated with Domainex, a medicines research service partner, as a partner to provide integrated drug discovery services for its research programs. Amphista will benefit from the expertise in protein production, assay biology, and medicinal chemistry of Domainex.
Why Purchase the Report?
- To visualize the global drug discovery outsourcing services market segmentation based on service type, drug type, therapeutic areas, end user and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analysing trends and co-development.
- Excel data sheet with numerous data points of drug discovery outsourcing services market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global drug discovery outsourcing services market report would provide approximately 61 tables, 58 figures and 187 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Service Type
- 3.2. Snippet by Drug Type
- 3.3. Snippet by Therapeutic Areas
- 3.4. Snippet by End User
- 3.5. Snippet by Region
4. Market Dynamics
- 4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.1.1. Rise in the AI-enabled drug discovery methods
- 4.1.1.2. Rise in the prevalence of chronic diseases
- 4.1.2. Restraints
- 4.1.2.1. High cost of drug discovery
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Pipeline Analysis
- 5.6. Unmet Needs
- 5.7. DMI Opinion
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
7. By Service Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
- 7.1.2. Market Attractiveness Index, By Service Type
- 7.2. Medical Chemistry Services*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Biology Services
8. By Drug Type
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 8.1.2. Market Attractiveness Index, By Drug Type
- 8.2. Small Molecule *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Large Molecules (Biopharmaceuticals)
9. By Therapeutic Areas
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
- 9.1.2. Market Attractiveness Index, By Therapeutic Areas
- 9.2. Oncology *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Infectious Disease
- 9.4. Respiratory Disease
- 9.5. Cardiovascular
- 9.6. Gastrointestinal
- 9.7. Others
10. By End User
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
- 10.2. Contract Research Organizations*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Pharmaceutical & Biotechnology Companies
- 10.4. Academic Institutes
- 10.5. Others
11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.7.1. U.S.
- 11.2.7.2. Canada
- 11.2.7.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.7.1. Germany
- 11.3.7.2. UK
- 11.3.7.3. France
- 11.3.7.4. Italy
- 11.3.7.5. Spain
- 11.3.7.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.7.1. Brazil
- 11.4.7.2. Argentina
- 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.6.1. China
- 11.5.6.2. India
- 11.5.6.3. Japan
- 11.5.6.4. Australia
- 11.5.6.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Areas
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
13. Company Profiles
- 13.1. ThermoFisher Scientific*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. Charles River Laboratories International, Inc
- 13.3. WuXi AppTec Co., Ltd.,
- 13.4. Albany Molecular Research, Inc.,
- 13.5. Aragen Life Sciences Ltd
- 13.6. Sygnature Discovery,
- 13.7. Pharmaron Beijing Co., Ltd.,
- 13.8. Domainex Ltd.,
- 13.9. Jubilant Biosys Ltd.
- 13.10. Evotec
LIST NOT EXHAUSTIVE
14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
